ARTICLE | Clinical News
Corixa reports HLA-dependent response in Melacine trials
October 30, 2000 8:00 AM UTC
CRXA announced analyses of a Phase III trial with Melacine in 689 patients with stage II melanoma in which extension of disease-free survival was seen in patients receiving vaccination following surgi...